Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo and Active-controlled, Parallel-group, Multicentre Clinical Study

Next Previous
Trial Profile

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon Treated With Levodopa Plus a Dopa Decarboxylase Inhibitor (DDCI): a Double-blind, Randomised, Placebo and Active-controlled, Parallel-group, Multicentre Clinical Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Opicapone (Primary) ; Benserazide; Carbidopa; Entacapone; Levodopa
  • Indications Parkinson's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms BIPARK-I
  • Sponsors Bial; BIAL - Portela C S.A.

Most Recent Events

  • 18 Sep 2022 Results (n=237) of a Post-Hoc Analysis of BIPARK-I, presented at the 26th International Congress of Parkinson's Disease and Movement Disorders
  • 06 Jun 2022 According to a Neurocrine Biosciences media release, Results of post-hoc analysis of ( NCT01568073 and NCT01227655) are being shared at SLEEP 2022, the annual meeting of the Associated Professional Sleep Societies, LLC (APSS) being held June 4-8 in Charlotte, North Carolina. The oral presentation of these data will take place on June 8
  • 06 Jun 2022 Results of post-hoc analysis of ( NCT01568073 and NCT01227655) published in the Neurocrine Biosciences Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top